| AASLD

Sanjay Govil, Naresh P. Shanmugam, Mettu S. Reddy, Gomathy Narasimhan, Mohamed Rela – 29 June 2015

Reply

Read more about Reply

Phillip Hylemon, Masayuki Nagahashi, Kazuaki Takabe, Huiping Zhou – 29 June 2015

Prophylaxis of HCV reinfection and direct‐acting antiviral agents during liver transplantation

Read more about Prophylaxis of HCV reinfection and direct‐acting antiviral agents during liver transplantation

Marcello Tavio, Marco Vivarelli, Stefano Menzo, Andrea Gori, Paolo Antonio Grossi, Anna Marigliano – 29 June 2015

Negative feedback regulation of bile acid metabolism: Impact on liver metabolism and diseases

Read more about Negative feedback regulation of bile acid metabolism: Impact on liver metabolism and diseases

John Y.L. Chiang – 29 June 2015

Alisporivir plus ribavirin, interferon free or in combination with pegylated interferon, for hepatitis C virus genotype 2 or 3 infection

Read more about Alisporivir plus ribavirin, interferon free or in combination with pegylated interferon, for hepatitis C virus genotype 2 or 3 infection

Jean‐Michel Pawlotsky, Robert Flisiak, Shiv K. Sarin, Jens Rasenack, Teerha Piratvisuth, Wan‐Long Chuang, Cheng‐Yuan Peng, Graham R. Foster, Samir Shah, Heiner Wedemeyer, Christophe Hézode, Wei Zhang, Kelly A. Wong, Bin Li, Claudio Avila, Nikolai V. Naoumov, on behalf of the VITAL‐1 study team – 27 June 2015 – Alisporivir is a cyclophilin inhibitor with pan‐genotypic anti–hepatitis C virus (HCV) activity and a high barrier to viral resistance. The VITAL‐1 study assessed alisporivir as interferon (IFN)‐free therapy in treatment‐naïve patients infected with HCV genotype 2 or 3.